News FDA fast-tracks Teva's coeliac disease treatment Teva gets fast-track status from the FDA for a coeliac disease drug with a mechanism that has proved tough to crack.
News Equillium triples clinical pipeline with $329m Bioniz takeov... Equillium has announced another bolt-on deal to expand its pipeline tripling the size of its clinical pipeline to three drug candidates via a $329 million agreement to acquire Bioniz Therap
News Takeda buys US biotech PvP Biologics for $330 million Takeda has bought US biotech PvP Biologics for $330 million, adding a potential new form of therapy for coeliac disease to its pipeline.
News Takeda buys coeliac drug licence from COUR Pharmaceuticals Takeda has bought a licence for a coeliac disease drug from COUR Pharmaceuticals, after the US biotech announced supportive phase 2a trial data.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
